Beatson West of Scotland Cancer Centre | Clinical Trials Unit

Research site
Level 0, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, Glasgow City, Scotland
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


75 of 251
Status: Active
Trial type: Interventional
Funder type: Industry

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

An open-label, controlled, multi-site, interventional, 2-arm, Phase II trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy...

Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer
Biological: BNT113
Biological: Pembrolizumab

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Waldenstrom Macroglobulinemia
Follicular Lymphoma
Drug: Ibrutinib

Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplast...

Active, not recruiting
Bone Marrow Disease
Drug: Ruxolitinib
Drug: Pelabresib (CPI-0610)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Drug: Physician's Choice medications
Drug: Pacritinib

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with p...

Active, not recruiting
Cancer of Unknown Primary Site
Drug: Pemigatinib
Drug: Entrectinib

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituxima...

Diffuse Large B-cell Lymphoma
Drug: Oxaliplatin
Drug: Rituxumab

This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head...

Active, not recruiting
Squamous Cell Carcinoma of the Head and Neck
Drug: Tiragolumab
Drug: Carboplatin

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally...

Breast Cancer
Drug: Bevacizumab
Drug: Capecitabine

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in pa...

Non-Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Divarasib

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to...

Metastatic Cancer
Advanced Cancer
Drug: ART0380
Drug: Gemcitabine

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in particip...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Tiragolumab
Drug: Durvalumab

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetic...

Active, not recruiting
Drug: Atezolizumab Placebo
Drug: Vemurafenib

The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) tre...

Active, not recruiting
Squamous Cell Carcinoma of Head and Neck
Drug: Tiragolumab
Drug: Atezolizumab

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Lo...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with pr...

Carcinoma, Hepatocellular
Drug: E7386
Drug: Lenvatinib

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients wit...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor ac...

Active, not recruiting
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Drug: Linagliptin
Drug: Cobimetinib

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in pa...

Triple Negative Breast Cancer (TNBC)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Drug: NX-1607
Drug: Paclitaxel

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who prog...

Active, not recruiting
Gastrointestinal Stromal Tumors
Drug: Sunitinib
Drug: Ripretinib

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Drug: DS-8201a
Drug: T-DM1

Trial conditions

Breast Cancer (31 trials)
Carcinoma (27 trials)
Lymphoma (21 trials)
Cancer (20 trials)
Non-Small-Cell Lung Carc... (19 trials)
Lung Cancer (17 trials)
Ovarian Epithelial Carci... (17 trials)
Ovarian Cancer (15 trials)
Leukemia (13 trials)
Renal Cell Carcinoma (12 trials)

And 90 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems